In our patient cohort, the group with severe Hb loss had significantly more peripheral arterial disease with platelet aggregation inhibitors, which may have contributed to a higher bleeding tendency and more severe periprocedural blood loss. Here, GSTM1 is linked to peripheral arterial disease.